AVP and Hypertension: End-organ-targeted pharmacological interventions, such as tolvaptan, have demonstrated benefit against AVP-mediated fluid retention [15], but remain insufficient to address the full spectrum of PD-related complications linked to AVP, including hypertension and immune dysregulation.